First-of-its-kind, cloud-native AI platform for transplant program cohort analysis, clinical research, and real-world evidence generation announced at the 2026 Precision Medicine World Conference

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the launch of VANTx™, an AI‑powered, cloud‑native clinical data and analytics platform designed to transform complex transplant data into insights that support clinical research and real‑world evidence development.

VANTx is designed for secure, scalable cohort analysis across longitudinal patient timelines that enables the evaluation of treatment trends, patient outcomes, and practice patterns. The platform is intended to support clinicians, transplant programs, and pharma partners in testing hypotheses to generate actionable findings for treatment protocol development, investigator-initiated studies, and clinical trial design.

Jing Huang, Chief Data and AI Officer of CareDx, will be introducing VANTx at the Precision Medicine World Conference (PMWC) in Silicon Valley, California, on March 5, 2026, during the session “Transforming Transplant Care Through AI: From Predictive Insights to Precision Decisions.” The presentation will take place as part of the “AI in Clinical Decision Support” track.

“As the market leader in transplant precision diagnostics and patient care solutions, we can help our transplant center partners generate actionable insights using LLMs and other models.” said Jing Huang, Chief Data and AI Officer at CareDx. “I joined CareDx to lead the development of the VANTx platform and to help transplant teams and researchers make sense of complex, longitudinal data in a way that is intuitive, clinically meaningful, and actionable. I am thrilled to see this vision and the investment we have made over the past 24 months in AI architecture starting to become a reality in support of transplant care globally.”

VANTx operates on a live data pipeline of CareDx’s continuously expanding, multidimensional data repository of de-identified molecular tests and clinical trial data, with the ability to incorporate additional data at the transplant center’s request including EMR, care quality, and remote patient monitoring data. VANTx receives real‑time ingestion from laboratory and clinical data sources and is built on a Databricks environment that leverages the Llama 3 foundational model and other advanced machine-learning techniques optimized for structured clinical data. Additionally, VANTx will incorporate validated predictive and prognostic insights models from KOAR, SHORE, ALAMO, and MAPLE with the goal of supporting kidney, heart, lung, and liver transplant research, respectively. These models are intended to inform sub-analyses of predicted disease risk in areas of significant research interest to the clinical community such as delayed graft function, microvascular inflammation, antibody mediated rejection, cardiac allograft vasculopathy, and cancer risk.

VANTx is available to transplant centers through consultation with CareDx’s medical affairs team today, and the company intends to make it available through self-service permission-based access to clinicians later in 2026.

About CareDx

CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients. For more information, please visit www.caredx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx including statements regarding the potential benefits and results that may be achieved with VANTx, AlloSure, AlloMap, and HeartCare. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of VANTx, AlloSure, AlloMap, and HeartCare, risks that the findings in the data may be inaccurate, general economic and market factors, and other risks discussed in CareDx’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by CareDx with the SEC on February 25, 2026, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260305457319/en/